Published in J Am Soc Nephrol on September 23, 2011
Trial of Plasma Exchange for Severe Crescentic IgA NEphropathy (RESCUE) | NCT02647255
Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis. PLoS Genet (2012) 1.69
Novel lectin-independent approach to detect galactose-deficient IgA1 in IgA nephropathy. Nephrol Dial Transplant (2015) 1.49
Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy. J Am Soc Nephrol (2012) 1.40
Toll-Like Receptor 9 Stimulation Induces Aberrant Expression of a Proliferation-Inducing Ligand by Tonsillar Germinal Center B Cells in IgA Nephropathy. J Am Soc Nephrol (2016) 1.39
The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression. Kidney Int (2012) 1.31
Association of C4d deposition with clinical outcomes in IgA nephropathy. Clin J Am Soc Nephrol (2014) 1.28
The genetics and immunobiology of IgA nephropathy. J Clin Invest (2014) 1.22
Prediction of outcomes in crescentic IgA nephropathy in a multicenter cohort study. J Am Soc Nephrol (2013) 1.20
Variants in Complement Factor H and Complement Factor H-Related Protein Genes, CFHR3 and CFHR1, Affect Complement Activation in IgA Nephropathy. J Am Soc Nephrol (2014) 1.11
Glycosylation of IgA1 and pathogenesis of IgA nephropathy. Semin Immunopathol (2012) 1.09
Decreased circulating C3 levels and mesangial C3 deposition predict renal outcome in patients with IgA nephropathy. PLoS One (2012) 1.08
Cytokines alter IgA1 O-glycosylation by dysregulating C1GalT1 and ST6GalNAc-II enzymes. J Biol Chem (2014) 1.06
Naturally occurring structural isomers in serum IgA1 o-glycosylation. J Proteome Res (2011) 1.05
New developments in the genetics, pathogenesis, and therapy of IgA nephropathy. Kidney Int (2015) 1.04
Urinary extracellular vesicles as source of biomarkers in kidney diseases. Front Immunol (2015) 1.00
Serum levels of galactose-deficient immunoglobulin (Ig) A1 and related immune complex are associated with disease activity of IgA nephropathy. Clin Exp Nephrol (2014) 1.00
Current Understanding of the Role of Complement in IgA Nephropathy. J Am Soc Nephrol (2015) 0.99
Overview of the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Clin Exp Nephrol (2013) 0.98
Biomarkers in IgA nephropathy: relationship to pathogenetic hits. Expert Opin Med Diagn (2013) 0.96
A panel of serum biomarkers differentiates IgA nephropathy from other renal diseases. PLoS One (2014) 0.95
Aberrant O-glycosylation and anti-glycan antibodies in an autoimmune disease IgA nephropathy and breast adenocarcinoma. Cell Mol Life Sci (2012) 0.89
New Insights into the Pathogenesis of IgA Nephropathy. Kidney Dis (Basel) (2015) 0.87
Anti-glomerular basement membrane nephritis: why we still 'need' the kidney biopsy. Clin Kidney J (2012) 0.85
Association of systemic lupus erythematosus susceptibility genes with IgA nephropathy in a Chinese cohort. Clin J Am Soc Nephrol (2014) 0.85
Use of eculizumab in crescentic IgA nephropathy: proof of principle and conundrum? Clin Kidney J (2015) 0.84
IgA1 Glycosylation Is Heritable in Healthy Twins. J Am Soc Nephrol (2016) 0.83
The combined role of galactose-deficient IgA1 and streptococcal IgA-binding M Protein in inducing IL-6 and C3 secretion from human mesangial cells: implications for IgA nephropathy. J Immunol (2014) 0.83
The gut-kidney axis in IgA nephropathy: role of microbiota and diet on genetic predisposition. Pediatr Nephrol (2017) 0.83
The Origin and Activities of IgA1-Containing Immune Complexes in IgA Nephropathy. Front Immunol (2016) 0.83
Diagnosis and activity assessment of immunoglobulin A nephropathy: current perspectives on noninvasive testing with aberrantly glycosylated immunoglobulin A-related biomarkers. Int J Nephrol Renovasc Dis (2014) 0.82
Enzymatic sialylation of IgA1 O-glycans: implications for studies of IgA nephropathy. PLoS One (2014) 0.82
Uncoupling of glomerular IgA deposition and disease progression in alymphoplasia mice with IgA nephropathy. PLoS One (2014) 0.82
[Vasculitis. New nomenclature of the Chapel Hill consensus conference 2012]. Pathologe (2013) 0.81
A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction. J Am Soc Nephrol (2016) 0.81
Astragalus membranaceus up-regulate Cosmc expression and reverse IgA dys-glycosylation in IgA nephropathy. BMC Complement Altern Med (2014) 0.81
Increased urinary CD80 excretion and podocyturia in Fabry disease. J Transl Med (2016) 0.80
Elucidating heterogeneity of IgA1 hinge-region O-glycosylation by use of MALDI-TOF/TOF mass spectrometry: role of cysteine alkylation during sample processing. J Proteomics (2013) 0.80
The kinetics of glomerular deposition of nephritogenic IgA. PLoS One (2014) 0.80
Complement involvement in kidney diseases: From physiopathology to therapeutical targeting. World J Nephrol (2015) 0.80
[Vasculitis: New nomenclature of the Chapel Hill consensus conference 2012]. Z Rheumatol (2014) 0.80
Pathological scenario with the mannose-binding lectin in patients with IgA nephropathy. J Biomed Biotechnol (2012) 0.79
FCGR2B and FCRLB gene polymorphisms associated with IgA nephropathy. PLoS One (2013) 0.79
Somatic Mutations Modulate Autoantibodies against Galactose-Deficient IgA1 in IgA Nephropathy. J Am Soc Nephrol (2016) 0.79
Serum galactose-deficient IgA1 level is not associated with proteinuria in children with IgA nephropathy. Int J Nephrol (2012) 0.79
Suppression of adiponectin by aberrantly glycosylated IgA1 in glomerular mesangial cells in vitro and in vivo. PLoS One (2012) 0.79
C4d deposits in IgA nephropathy: where does complement activation come from? Pediatr Nephrol (2017) 0.78
Biomarkers and targeted new therapies for IgA nephropathy. Pediatr Nephrol (2016) 0.78
In vitro-generated immune complexes containing galactose-deficient IgA1 stimulate proliferation of mesangial cells. Results Immunol (2012) 0.78
Corticosteroids in IgA Nephropathy: Lessons from Recent Studies. J Am Soc Nephrol (2016) 0.78
Podocin is translocated to cytoplasm in puromycin aminonucleoside nephrosis rats and in poor-prognosis patients with IgA nephropathy. Cell Tissue Res (2015) 0.78
Cumulative effects of variants identified by genome-wide association studies in IgA nephropathy. Sci Rep (2014) 0.78
Pathological sub-analysis of a multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy versus steroid pulse monotherapy in patients with immunoglobulin A nephropathy. Clin Exp Nephrol (2015) 0.78
N-acetylgalactosaminide α2,6-sialyltransferase II is a candidate enzyme for sialylation of galactose-deficient IgA1, the key autoantigen in IgA nephropathy. Nephrol Dial Transplant (2014) 0.77
Galactose-Deficient IgA1 as a Candidate Urinary Polypeptide Marker of IgA Nephropathy? Dis Markers (2016) 0.77
Effects of rhein on intestinal epithelial tight junction in IgA nephropathy. World J Gastroenterol (2013) 0.77
Targeted IgA Fc receptor I (FcαRI) therapy in the early intervention and treatment of pristane-induced lupus nephritis in mice. Clin Exp Immunol (2015) 0.77
Comparison of methods of steroid administration combined with tonsillectomy for IgA nephropathy patients. Clin Exp Nephrol (2016) 0.77
In IgA Nephropathy, Glomerulosclerosis Is Associated with Increased Urinary CD80 Excretion and Urokinase-Type Plasminogen Activator Receptor-Positive Podocyturia. Nephron Extra (2017) 0.76
Clinical manifestations of Henoch-Schönlein purpura nephritis and IgA nephropathy: comparative analysis of data from the Japan Renal Biopsy Registry (J-RBR). Clin Exp Nephrol (2015) 0.76
Development of Animal Models of Human IgA Nephropathy. Drug Discov Today Dis Models (2014) 0.76
Update on immunoglobulin A nephropathy, Part I: Pathophysiology. World J Nephrol (2015) 0.76
Induction of IgA deposits and glomerulonephritis by IgA rheumatoid factor. J Am Soc Nephrol (2012) 0.76
IgA nephropathy enigma. Clin Immunol (2016) 0.75
Novel biomarkers in glomerular disease. Adv Chronic Kidney Dis (2014) 0.75
Multiple rare genetic variants co-segregating with familial IgA nephropathy all act within a single immune-related network. J Intern Med (2016) 0.75
Association of IgG co-deposition with serum levels of galactose-deficient IgA1 in pediatric IgA nephropathy. Clin Nephrol (2012) 0.75
Concurrent Drug-Induced Linear Immunoglobulin A Dermatosis and Immunoglobulin A Nephropathy. Ann Dermatol (2015) 0.75
Update on immunoglobulin a nephropathy. Part II: Clinical, diagnostic and therapeutical aspects. World J Nephrol (2016) 0.75
IgA nephropathy in a laboratory worker that progressed to end-stage renal disease: a case report. Ann Occup Environ Med (2016) 0.75
Cellular signaling and production of galactose-deficient IgA1 in IgA nephropathy, an autoimmune disease. J Immunol Res (2014) 0.75
UMOD polymorphism rs12917707 is not associated with severe or stable IgA nephropathy in a large Caucasian cohort. BMC Nephrol (2014) 0.75
Effect of Immunosuppressive Drugs on the Changes of Serum Galactose-Deficient IgA1 in Patients with IgA Nephropathy. PLoS One (2016) 0.75
The solution structures of native and patient monomeric human IgA1 reveal asymmetric extended structures: implications for function and IgAN disease. Biochem J (2015) 0.75
In Acute IgA Nephropathy, Proteinuria and Creatinine Are in the Spot, but Podocyturia Operates in Silence: Any Place for Amiloride? Case Rep Nephrol (2017) 0.75
Inflammation in IgA nephropathy. Pediatr Nephrol (2017) 0.75
[Skin manifestations of different forms of vasculitis]. Z Rheumatol (2013) 0.75
[Intercapillary deposits of IgA-IgG]. J Urol Nephrol (Paris) (1968) 4.44
Common variants at five new loci associated with early-onset inflammatory bowel disease. Nat Genet (2009) 3.82
Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. Kidney Int (2007) 3.17
Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet (2011) 3.15
Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest (2009) 2.82
Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J Clin Invest (1999) 2.77
Immunostaining findings in IgA nephropathy: correlation with histology and clinical outcome in the Oxford classification patient cohort. Nephrol Dial Transplant (2011) 2.51
Balancing selection and heterogeneity across the classical human leukocyte antigen loci: a meta-analytic review of 497 population studies. Hum Immunol (2008) 2.22
IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1. J Clin Invest (2008) 2.15
IgA1-containing immune complexes in IgA nephropathy differentially affect proliferation of mesangial cells. Kidney Int (2005) 2.08
Protein glycosylation: chaperone mutation in Tn syndrome. Nature (2005) 2.04
Cloning and expression of human core 1 beta1,3-galactosyltransferase. J Biol Chem (2001) 1.98
An imbalance of human complement regulatory proteins CFHR1, CFHR3 and factor H influences risk for age-related macular degeneration (AMD). Hum Mol Genet (2010) 1.95
The Fab and Fc fragments of IgA1 exhibit a different arrangement from that in IgG: a study by X-ray and neutron solution scattering and homology modelling. J Mol Biol (1999) 1.92
Interactions of human mesangial cells with IgA and IgA-containing immune complexes. Kidney Int (2002) 1.88
IgA immune complexes in Henoch-Schönlein purpura. Lancet (1979) 1.85
Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy. J Am Soc Nephrol (2008) 1.76
HLA has strongest association with IgA nephropathy in genome-wide analysis. J Am Soc Nephrol (2010) 1.64
Insights into IgA-mediated immune responses from the crystal structures of human FcalphaRI and its complex with IgA1-Fc. Nature (2003) 1.53
Determination of aberrant O-glycosylation in the IgA1 hinge region by electron capture dissociation fourier transform-ion cyclotron resonance mass spectrometry. J Biol Chem (2005) 1.50
Reactivities of N-acetylgalactosamine-specific lectins with human IgA1 proteins. Mol Immunol (2007) 1.45
Comparison of methods for profiling O-glycosylation: Human Proteome Organisation Human Disease Glycomics/Proteome Initiative multi-institutional study of IgA1. Mol Cell Proteomics (2009) 1.45
Analysis of O-glycan heterogeneity in IgA1 myeloma proteins by Fourier transform ion cyclotron resonance mass spectrometry: implications for IgA nephropathy. Anal Bioanal Chem (2007) 1.37
Incidence of latent mesangial IgA deposition in renal allograft donors in Japan. Kidney Int (2003) 1.36
Identification of the transferrin receptor as a novel immunoglobulin (Ig)A1 receptor and its enhanced expression on mesangial cells in IgA nephropathy. J Exp Med (2001) 1.35
IgA nephropathy: an update. Curr Opin Nephrol Hypertens (2004) 1.35
Glycosylation and size of IgA1 are essential for interaction with mesangial transferrin receptor in IgA nephropathy. J Am Soc Nephrol (2004) 1.33
Toll-like receptor 9 affects severity of IgA nephropathy. J Am Soc Nephrol (2008) 1.31
Genetic studies of IgA nephropathy: past, present, and future. Pediatr Nephrol (2010) 1.30
Electrophoretic methods for analysis of urinary polypeptides in IgA-associated renal diseases. Electrophoresis (2007) 1.26
Clustered O-glycans of IgA1: defining macro- and microheterogeneity by use of electron capture/transfer dissociation. Mol Cell Proteomics (2010) 1.21
IgA-containing circulating immune complexes in dermatitis herpetiformis, Henoch-Schönlein purpura, systemic lupus erythematosus and other diseases. Clin Exp Immunol (1980) 1.19
Role of aberrant glycosylation of IgA1 molecules in the pathogenesis of IgA nephropathy. Kidney Blood Press Res (2008) 1.18
IgA nephropathy and Henoch-Schoenlein purpura nephritis: aberrant glycosylation of IgA1, formation of IgA1-containing immune complexes, and activation of mesangial cells. Contrib Nephrol (2007) 1.17
Frequency of mesangial IgA deposits in a non-selected autopsy series. Nephrol Dial Transplant (1989) 1.17
Serum under-galactosylated IgA1 is increased in Japanese patients with IgA nephropathy. Nephrol Dial Transplant (2008) 1.17
Podocyte injury induced by mesangial-derived cytokines in IgA nephropathy. Nephrol Dial Transplant (2008) 1.16
Immunoglobulin and complement deposition in glomeruli of 756 subjects who had committed suicide or met with a violent death. J Clin Pathol (1993) 1.14
O-glycosylation of serum IgA1 antibodies against mucosal and systemic antigens in IgA nephropathy. J Am Soc Nephrol (2006) 1.11
Initiation of O-glycan synthesis in IgA1 hinge region is determined by a single enzyme, UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 2. J Biol Chem (2002) 1.09
IgA-containing immune complexes in the urine of IgA nephropathy patients. Nephrol Dial Transplant (2006) 1.09
Quantitation of saccharide compositions of O-glycans by mass spectrometry of glycopeptides and its application to rheumatoid arthritis. J Proteome Res (2010) 1.08
Activation of podocytes by mesangial-derived TNF-alpha: glomerulo-podocytic communication in IgA nephropathy. Am J Physiol Renal Physiol (2008) 1.07
The mesangium and glomerulonephritis. Klin Wochenschr (1982) 1.04
Engagement of transferrin receptor by polymeric IgA1: evidence for a positive feedback loop involving increased receptor expression and mesangial cell proliferation in IgA nephropathy. J Am Soc Nephrol (2005) 1.04
Recognition of galactose-deficient O-glycans in the hinge region of IgA1 by N-acetylgalactosamine-specific snail lectins: a comparative binding study. Biochemistry (2010) 1.02
Absence of CD89, polymeric immunoglobulin receptor, and asialoglycoprotein receptor on human mesangial cells. J Am Soc Nephrol (2000) 1.02
Identification and characterization of CMP-NeuAc:GalNAc-IgA1 alpha2,6-sialyltransferase in IgA1-producing cells. J Mol Biol (2007) 1.02
Analysis of IgA1 N-glycosylation and its contribution to FcalphaRI binding. Biochemistry (2008) 1.00
The pathogenesis of IgA nephropathy. Curr Opin Nephrol Hypertens (2011) 1.00
Glycosylation of IgA is required for optimal activation of the alternative complement pathway by immune complexes. Immunology (1994) 0.97
Disappearance of glomerular mesangial IgA deposits after renal allograft transplantation. Transplantation (1982) 0.91
IgA nephropathy at two score and one. Kidney Int (2009) 0.90
Evaluation of the specific structures of IgA1 hinge glycopeptide in 30 IgA nephropathy patients by mass spectrometry. J Nephrol (2010) 0.86
The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int (2009) 7.45
The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int (2009) 7.19
Mutations in kelch-like 3 and cullin 3 cause hypertension and electrolyte abnormalities. Nature (2012) 4.26
Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet (2011) 3.15
Renal outcome in patients with congenital anomalies of the kidney and urinary tract. Kidney Int (2009) 3.13
Primary intestinal epithelial cells selectively transfer R5 HIV-1 to CCR5+ cells. Nat Med (2002) 3.04
SNO-hemoglobin is not essential for red blood cell-dependent hypoxic vasodilation. Nat Med (2008) 3.02
IgA nephropathy. N Engl J Med (2013) 2.96
Clinical proteomics: A need to define the field and to begin to set adequate standards. Proteomics Clin Appl (2007) 2.84
Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest (2009) 2.82
SIVcpz in wild chimpanzees. Science (2002) 2.45
Atrial natriuretic peptide inhibits transforming growth factor beta-induced Smad signaling and myofibroblast transformation in mouse cardiac fibroblasts. Circ Res (2007) 2.32
C1q nephropathy: features at presentation and outcome. Pediatr Nephrol (2005) 2.29
The structural basis of 5' triphosphate double-stranded RNA recognition by RIG-I C-terminal domain. Structure (2010) 2.29
Autoimmunity in membranous nephropathy targets aldose reductase and SOD2. J Am Soc Nephrol (2010) 2.22
IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1. J Clin Invest (2008) 2.15
The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults. Kidney Int (2010) 2.14
Urinary proteomics in diabetes and CKD. J Am Soc Nephrol (2008) 2.12
IgA1-containing immune complexes in IgA nephropathy differentially affect proliferation of mesangial cells. Kidney Int (2005) 2.08
Allelism of MCKD, FJHN and GCKD caused by impairment of uromodulin export dynamics. Hum Mol Genet (2003) 2.01
Aberrant glycosylation of IgA1 is inherited in both pediatric IgA nephropathy and Henoch-Schönlein purpura nephritis. Kidney Int (2011) 2.01
Mutations in SEC63 cause autosomal dominant polycystic liver disease. Nat Genet (2004) 1.96
Sex steroid hormones, hormonal contraception, and the immunobiology of human immunodeficiency virus-1 infection. Endocr Rev (2009) 1.95
Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics (2010) 1.90
Interactions of human mesangial cells with IgA and IgA-containing immune complexes. Kidney Int (2002) 1.88
The Fap1 fimbrial adhesin is a glycoprotein: antibodies specific for the glycan moiety block the adhesion of Streptococcus parasanguis in an in vitro tooth model. Mol Microbiol (2002) 1.88
The chicken yolk sac IgY receptor, a functional equivalent of the mammalian MHC-related Fc receptor, is a phospholipase A2 receptor homolog. Immunity (2004) 1.88
Mycobacterium tuberculosis WhiB3 maintains redox homeostasis by regulating virulence lipid anabolism to modulate macrophage response. PLoS Pathog (2009) 1.87
Rituximab in children with resistant idiopathic nephrotic syndrome. J Am Soc Nephrol (2012) 1.83
The RIG-I-like receptor LGP2 recognizes the termini of double-stranded RNA. J Biol Chem (2009) 1.78
Advances in urinary proteome analysis and biomarker discovery. J Am Soc Nephrol (2007) 1.77
Clinical trial to evaluate omega-3 fatty acids and alternate day prednisone in patients with IgA nephropathy: report from the Southwest Pediatric Nephrology Study Group. Clin J Am Soc Nephrol (2006) 1.76
Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy. J Am Soc Nephrol (2008) 1.76
Hypertension with or without adrenal hyperplasia due to different inherited mutations in the potassium channel KCNJ5. Proc Natl Acad Sci U S A (2012) 1.74
A zinc-dependent adhesion module is responsible for intercellular adhesion in staphylococcal biofilms. Proc Natl Acad Sci U S A (2008) 1.70
Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis. PLoS Genet (2012) 1.69
Brief communication: Glomerulonephritis in patients with hepatitis C cirrhosis undergoing liver transplantation. Ann Intern Med (2006) 1.68
APOL1 Genotype and Kidney Transplantation Outcomes From Deceased African American Donors. Transplantation (2016) 1.68
APOL1 variants increase risk for FSGS and HIVAN but not IgA nephropathy. J Am Soc Nephrol (2011) 1.67
IgA glycosylation and IgA immune complexes in the pathogenesis of IgA nephropathy. Semin Nephrol (2008) 1.64
Copy-number disorders are a common cause of congenital kidney malformations. Am J Hum Genet (2012) 1.63
Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol (2011) 1.62
A linear lattice model for polyglutamine in CAG-expansion diseases. Proc Natl Acad Sci U S A (2002) 1.62
End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. Arthritis Rheumatol (2014) 1.62
Mucosal immunoglobulins. Immunol Rev (2005) 1.60
Recommendations for biomarker identification and qualification in clinical proteomics. Sci Transl Med (2010) 1.59
Paucity of antigen-specific IgA responses in sera and external secretions of HIV-type 1-infected individuals. AIDS Res Hum Retroviruses (2004) 1.58
CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics. Proteomics Clin Appl (2008) 1.57
Predialysis versus postdialysis hematocrit evaluation during erythropoietin therapy. Am J Kidney Dis (2002) 1.57
The rediscovery of uromodulin (Tamm-Horsfall protein): from tubulointerstitial nephropathy to chronic kidney disease. Kidney Int (2011) 1.56
Genomic imbalances in pediatric patients with chronic kidney disease. J Clin Invest (2015) 1.56
Immunologic uniqueness of the genital tract: challenge for vaccine development. Am J Reprod Immunol (2005) 1.54
Validation of the Oxford classification of IgA nephropathy. Kidney Int (2011) 1.53
Body fluid proteomics for biomarker discovery: lessons from the past hold the key to success in the future. J Proteome Res (2007) 1.52
Coexistence of different circulating anti-podocyte antibodies in membranous nephropathy. Clin J Am Soc Nephrol (2012) 1.51
Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins. Virology (2006) 1.51
Genetic determinants of mycophenolate-related anemia and leukopenia after transplantation. Transplantation (2011) 1.51
Determination of aberrant O-glycosylation in the IgA1 hinge region by electron capture dissociation fourier transform-ion cyclotron resonance mass spectrometry. J Biol Chem (2005) 1.50